Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 + Toripalimab in Advanced Urothelial Cancer
NCT06079112Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin in urothelial carcinoma (UC), sponsored by Mabwell. Started Sep 2023; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06079112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079112.